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ABSTRACT
Objective: The objective of the present work was to develop validated stability-indicating high-performance thin-layer chromatographic method 
for simultaneous estimation of formoterol fumarate dihydrate (FFD) and fluticasone propionate (FP) in bulk drug and pharmaceutical dosage form.
Methods: Pre-coated silica gel aluminum plates 60 F-254 were used as stationary phase. The mixture of toluene:ethyl acetate:formic acid (98%) 
(6:4:0.1; v/v/v) was used as a mobile phase. The densitometric quantification was carried out at 233 nm. The method was validated according to 
the ICH guidelines. The specificity and stability indicating the capability of the method were proven though degradation studies. Both drugs were 
subjected to acid (0.1N HCl) and base (0.1N NaOH) hydrolysis, oxidation (3% v/v H2O2), photolytic, and neutral degradation conditions.
Results: The selected mobile phase resolved peaks of FFD and FP with Rf values 0.27±0.10 and 0.64±0.10, respectively. Determination coefficients of 
calibration curves were found to be 0.998 and 0.999 in the range of 1–3.5 µg/spot and 10–60 µg/spot for FFD and FP with an accuracy of 99.09% for FFD 
and 99.20% for FP. The degradation products of FFD and FP were resolved from the pure drug with significant differences in their retention factor values. 
Conclusion: The developed method is simple, accurate and can be successfully applied for quantification of FFD and FP in bulk drug and pharmaceutical 
dosage form, contributing to improve the quality control and assure the therapeutic efficacy.
Keywords: Formoterol fumarate dihydrate, Fluticasone propionate, High-performance thin-layer chromatography, Stability-indicating method, 
Validation.
INTRODUCTION
Inhalation is currently the preferred route of drug delivery in asthma in 
accordance with a global initiative for asthma guideline [1], as it allows 
the release of drug directly to the site where the action is needed, thus 
minimizing systemic side effect. Inhaled corticosteroid in combination 
with a long-acting β2-agonist is the gold standard for the management 
of persistent asthma, with maximal local targeting and minimal 
systemic side effects. Formoterol fumarate dihydrate (FFD) is a long-
acting selective β-2 agonist used as a bronchodilator in the treatment 
of asthma. Chemically, FFD is a (E)-but-2-enedioic acid; N-[2-hydroxy-
5-[(1S)-1-hydroxy-2-[[(2S)-1-(4-methoxyphenyl) propan-2-yl] amino] 
ethyl] phenyl]formamide [2,3].
Fluticasone propionate (FP) is chemically 6α, 9-Difluoro-17-
[[(fluoromethyl) sulphanyl] carbonyl]-11β-hydroxy-16α-methyl-
3-oxoandrosta-1, 4-dien-17α-ylpropanoate. FP is a tri-fluorinated 
glucocorticoid specifically designed to provide enhanced anti-
inflammatory effect [2,4]. Both drugs are official in IP, BP, EP, and 
USP [5-8]. The chemical structures of FFD and FP [8] are shown in 
Fig. 1a and b, respectively.
Literature survey for FFD and FP revealed that various analytical 
methods using techniques such as high-performance liquid 
chromatography [9-20], spectrophotometry [18,21-25], and high-
performance thin-layer chromatography (HPTLC) [19,26] were 
reported for quantitative determination of single or multi-component 
systems. Gowekar and Wadher reported HPTLC method for 
simultaneous estimation of FFD and FP, but no degradation profile has 
been stated in the literature [27]. To the best of our knowledge, there 
is no stability indicating HPTLC method reported for the simultaneous 
estimation of FFD and FP in bulk drug and pharmaceutical dosage form.
Hence, the objective of the present work was to develop and validate 
the stability indicating HPTLC method for simultaneous estimation of 
FFD and FP in bulk drug and pharmaceutical dosage form.
METHODS
Chemicals and reagents
Gift samples of FFD and FP were procured from Vamsi Laboratories 
Pvt. Ltd. Solapur, Maharashtra, India. The pharmaceutical formulation 
of capsule Maxiflo-100 Rotacaps containing 6 μg of FFD and 100 μg 
of FP manufactured by Cipla Ltd. was procured from the market. All 
analytical grade chemicals and reagents used for the analysis were 
purchased from Merck, Mumbai, India.
Instrumentation
Pre-coated silica gel aluminum plates 60F-254 (20 cm×10 cm, 250 μm 
thickness, E. Merck, Darmstadt, Germany) supplied by Anchrom, Mumbai 
were used. The sampling was done by automated TLC sampler Linomat 
V applicator (Camag, Muttenz, Switzerland) which was controlled by 
Win-Cats software (V 3.15, Camag, Muttenz, Switzerland). The standard 
and sample solutions were spotted in the form of bands of width 6 mm 
with a Camag 100 μL sample (Hamilton, Bonaduz, Switzerland) syringe. 
Linear ascending development was carried out in a twin trough glass 
chamber (20 cm×10 cm, 10 cm×10 cm Camag, Muttenz, Switzerland). 
The mobile phase consisted of toluene:ethyl acetate:formic acid (98%) 
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(6:4:0.1; v/v/v). The developing solvent was run up to 80 mm and 
development was performed at room temperature (25°C±2°C) at a 
relative humidity of 60%±5%. The development time was 20 min. Plates 
were scanned at 233 nm with CAMAG TLC scanner 3. Deuterium lamp 
emitting a continuous UV spectrum between 200 and 400 nm was used 
as a source of radiation.
HPTLC method and chromatographic conditions
Preparation of standard stock solutions
Accurately weighed 10 mg of FFD was transferred to 10 ml volumetric 
flask, dissolved and diluted up to the mark with methanol (1 mg/ml).
Accurately weighed 10 mg of FP was transferred to 10 ml volumetric 
flask, dissolved and diluted up to the mark with chloroform (1 mg/ml).
Preparation of sample solution
Powder from 20 capsules (Maxiflo-100 Rotacaps containing 6 μg of 
FFD and 100 μg of FP per capsule) were weighed, their average weight 
determined (3.038 mg) and crushed to fine powder. The quantity of 
powder equivalent to 10 mg of FP and 0.6 mg of FFD was transferred 
into a 10 ml volumetric flask containing 5 ml of methanol and mixed 
well. The solution was ultrasonicated for 20 min, and then diluted to 
10 ml with methanol. The solution was filtered through Whatman filter 
paper (0.45 µm). The amount of each drug present in the sample was 
determined by comparing mean peak areas with that of the standard.
Prewashing of plates
Densitometric estimation was carried out on 20 cm×10 cm pre-coated 
silica gel 60F–254 plates from E. Merck. The plates were pre-washed with 
methanol, dried and activated for 15 min at 110°C before chromatography.
Selection of the solvent
Methanol and chloroform were selected as solvents for preparing 
sample solutions.
Selection of stationary phase
Identification and separation of FFD and FP were carried out on 
20 cm×10 cm, 10 cm×10 cm, pre-coated silica gel aluminum plates 60 
F-254 (250 μm thickness E. Merck, Darmstadt, Germany).
Sample application
The standard and formulation solution of FFD and FP was spotted on 
pre-coated TLC plates in the form of narrow bands of length 6 mm, 
at 8 mm from the bottom, and 10 mm distance between two bands. 
Samples were applied under continuous drying stream of nitrogen gas 
at constant application rate of150 nl/s.
Selection of wavelength
An evaluation was performed by linear regression of peak areas 
determined by UV absorption as a function of sample analysis at 
233 nm using methanol as a blank solution. The selection of detection 
wavelength is shown in Fig. 2.
Optimization of the mobile phase
Various solvent systems such as mixtures of (1) n-hexane:ethyl 
acetate:methanol:acetic acid (2.0:2.5:2.0:0.2; v/v/v/v), 
(2) n-hexane:ethyl acetate:methanol:formic acid (2.0:2.5:2.0:0.2; 
v/v/v/v), (3) n-hexane:ethyl acetate:acetic acid (5:10:0.2; v/v/v), and 
(4) toluene:ethyl acetate:formic acid (7:3:0.1; v/v/v) were tried to separate 
and resolve spots of FFD and FP from each other and other excipients of 
formulation. The mixture of n-hexane:ethyl acetate:methanol:acetic acid 
(2.0:2.5:2.0:0.2; v/v/v/v) and n-hexane:ethyl acetate:methanol:formic 
acid (2.0:2.5:2.0:0.2; v/v/v/v) provided well-resolved peaks but 
tailing was observed. Good peak shape was observed with a mixture of 
toluene:ethyl acetate:formic acid (7:3:0.1; v/v/v), but the FFD did not 
resolve from FP. Finally, the mixture of toluene:ethyl acetate:formic acid 
(6:4:0.1; v/v/v) showed well-resolved peaks with better peak shape. 
FFD and FP were satisfactorily resolved with Rf value 0.27±0.10 and 
0.64±0.10, respectively. Pre-saturation of TLC chamber with the mobile 
phase for 20 min assured better reproducibility in the migration of FFD 
and FP with better resolution which is shown in Fig. 3.
Method validation
The developed HPTLC method was validated as per the ICH guidelines 
Q1A (R2), Q1B, Q2 (R1) for linearity, precision, accuracy, limit of 
detection (LOD), limit of quantification (LOQ), and specificity [28-33].
Linearity
The linearity of the method was evaluated by constructing calibration 
curves at six concentration levels. Aliquots of standard working solution 
of FFD (1, 1.5, 2, 2.5, 3, and 3.5 µL) and (10, 20, 30, 40, 50, and 60 µL) 
of FP were applied on the plate, to obtain concentrations of 1, 1.5, 2, 
2.5, 3, and 3.5 μg/spot for FFD and 10, 20, 30, 40, 50, and 60 μg/spot 
for FP. The calibration curves were constructed by plotting peak area 
versus concentration with the help of Win-CATS software. The plate 
was developed in a twin trough glass chamber, using 20 min chamber 
saturation time. The length of the run was 80 mm. The developed plates 
were air-dried. Scanning was performed in UV mode at 233 nm. The slit 
dimension was kept at 5×0.45 mm at a scanning speed of 100 nm/s. 
Fig. 2: Overlay spectra for selection of detection wavelength 
(233 nm)
Fig. 1: (a) Chemical structure of formoterol fumarate dihydrate. (b) Chemical structure of fluticasone propionate
ba
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Slope, intercept, and coefficient of determination (r2) of the calibration 
curves were calculated to ascertain linearity of the method.
Precision
To evaluate intraday precision, three samples at three different 
concentrations were analyzed on the same day. The interday precision 
was studied by comparing assays performed on three different days.
The precision of an analytical method expresses the degree of scatter 
between a series of measurements obtained from multiple samples of 
the same homogeneous sample under prescribed conditions.
The intraday and interday variation for determination of FFD and FP 
were carried out at three different concentration levels 1.5, 2, and 2.5 
µg/spot for FFD and 20, 30, and 40 µg/spot for FP.
Repeatability
Repeatability of sample application was assessed by spotting 2 μg/
spot for FFD and 30 μg/spot FP of standard drug solution 6 times on 
a TLC plate at different times on the same day by sample applicator, 
followed by the development of plate and recording of the peak areas 
for six spots.
Accuracy
Accuracy studies were carried out at 80–120% levels, by mixing a 
known quantity of standard drug (0.5, 0.6, and 0.7 µg for FFD and 8, 10, 
and 12 µg for FP) with the sample formulation and the contents were 
analyzed by the proposed method.
Specificity
The specificity of the method was ascertained by analysis of drug 
standards and samples. The identities of the peaks for FFD and FP were 
confirmed by comparing the Rf with those of standards. The peak purity 
of FFD and FP was assessed by comparing their respective spectra at 
peak start, peak apex, and peak end positions of the spot.
Robustness
The proposed HPTLC method was tested for robustness. The 
parameters selected for the robustness study were, change in the 
amount of toluene in mobile phase composition, change in time 
from spotting to chromatography and time from chromatography to 
scanning, and change in saturation time. By introducing small changes 
in these parameters, the effect on the results was examined.
Limit of detection (LOD) and limit of quantitation (LOQ)
LOD and LOQ values represent the sensitivity of the proposed analytical 
method. To estimate the LOD and LOQ, blank methanol was spotted 6 
times. Different concentrations 0.1, 0.3, 0.5, 0.8, and 1 µg/spot for FFD 
Fig. 3: Typical densitogram of standard formoterol fumarate 
dihydrate peak 1 (Rf 0.27) and fluticasone propionate peak 
2 (Rf 0.64)
Fig. 4: Calibration curve of formoterol fumarate dihydrate  
(1–3.5 μg/spot)
Fig. 5: Calibration curve of fluticasone propionate (10–60 μg/spot)
Fig. 7: Residual plot of fluticasone propionate
Fig. 8: Typical densitogram of formoterol fumarate dihydrate and 
fluticasone propionate in the formulation
Fig. 6: Residual plot of formoterol fumarate dihydrate
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The neutral degradation of FFD and FP in combination was induced by 
refluxing them together with 10 ml of water at 50°C for 2 h. Samples 
were withdrawn (0.5 ml) at different time intervals for 2 h. 3 µL solution 
was applied on TLC plate in such a way that final concentration achieved 
was 1.8 µg/spot for FFD and 30 µg/spot for FP and densitograms were 
developed.
RESULTS
Optimization of chromatographic conditions
Toluene:ethyl acetate:formic acid (98%) (6:4:0.1 v/v/v/v) mixture 
provided best resolution with better peak shape. The Rf values were 
found to be 0.27 and 0.64 for FFD and FP, respectively.
Table 2: Precision studies for FFP and FP
Drug Precision Concentration (µg/spot) Area Average area Standard deviaton % RSD
FFD Intraday 1.5 1476 1452 1448 1460 15.14 1.03
2 1791 1798 1757 1782 21.93 1.23
2.5 2234 2204 2252 2230 24.24 1.08
Interday 1.5 1481 1462 1498 1480 18.00 1.21
2 1771 1742 1789 1767 23.71 1.34
2.5 2267 2244 2212 2241 27.62 1.23
FP Intraday 20 38152 38869 37878 38299 511.7 1.33
30 49962 49758 48935 49551 543.7 1.09
40 57998 57993 56901 57630 631.9 1.09
Interday 20 38282 37895 37248 37808 522.4 1.38
30 47989 48102 48966 48322 566.9 1.17
40 57767 56894 56587 57082 612.2 1.07
FFD: Formoterol fumarate dihydrate, FP: Fluticasone propionate, RSD: Relative standard deviation
Table 1: Linearity and range for FFD and FP
Linearity and range FFD FP
Range (µg/spot) 1–3.5 10–60
Regression coefficient (r2 ) 0.998 0.999
Linearity equation y=677.6x+472.73 y=1013.3x+10059
FFD: Formoterol fumarate dihydrate, FP: Fluticasone propionate
Fig. 9: Densitogram of degradation products of formoterol 
fumarate dihydrate (FFD) and fluticasone propionate in 0.1N HCL 
at 50°C after 30 min at Rf value 0.15 (peak 1; FFD 1), 0.47 (peak 3; 
FFD 2), and 0.72 (peak 5; FP 1), respectively
Fig. 10: Densitogram of degradation products of formoterol 
fumarate dihydrate (FFD) and fluticasone propionate (FP) in 0.1N 
NaOH at 50°C after 15 min at Rf value 0.42 (peak 2; FFD 3) and 
0.78 (peak 4; FP 2)
and 0.1, 0.2, 0.4, 0.6, and 0.8 µg/spot for FP were spotted. The peak was 
detected at 0.3 µg/spot for FFD and 0.2 µg/spot for FP with a signal-to-
noise ratio of 3:1. The peak was detected with the quantifiable area at 
1 µg/spot for FFD and 0.6 µg/spot for FP with a signal-to-noise ratio 
of 10:1.
Forced degradation studies
Acid- and base-induced degradation
To 6 mg of FFD and 100 mg of FP, 10 ml of 0.1 N HCl and 10 ml of 0.1 N 
NaOH were added separately and refluxed at 50°C for 1 h. Samples were 
withdrawn (0.5ml) at different time intervals for 1 h.
Further acidic and alkaline degradation were carried out for a 
combination of FFD and FP by refluxing them together with 10 
ml 0.1 N HCl and 10 ml 0.1 N NaOH at 50°C for 1 h. Samples were 
withdrawn (0.5 ml) at different time intervals for 1 h. 3 µL solution was 
applied on TLC plate in such a way that final concentration achieved was 
1.8 µg/spot for FFD and 30 µg/spot for FP and densitograms were 
developed.
Oxidative degradation
To 6 mg of FFD and 100 mg of FP, 10 ml of 3% H2O2 was added separately 
and refluxed at 50°C for 2 h. Samples were withdrawn (0.5 ml) at 
different time intervals for 2 h.
Further oxidative degradation was carried out for a combination of FFD 
and FP by refluxing them together with 10 ml of 3% H2O2 at 50°C for 
2 h. Samples were withdrawn (0.5 ml) at different time intervals for 
2 h. 3 µL solution was applied on TLC plate in such a way that final 
concentration achieved was 1.8 µg/spot for FFD and 30 µg/spot for FP 
and densitograms were developed.
Photolytic degradation
Solid forms of FFD and FP were exposed directly to sunlight during 
the daytime for 2 days to study their photolytic stability. Samples were 
weighed, dissolved and 3 µL solution was applied on TLC plate in such 
a way that final concentration achieved was 1.8 µg/spot for FFD and 
30 µg/spot for FP and densitograms were developed.
Neutral hydrolysis
To 6 mg of FFD and 100 mg of FP, 10 ml of water was added separately 
and refluxed at 50°C for 2 h. Samples were withdrawn (0.5 ml) at 
different time intervals for 2 h.
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Validation of the method
Linearity (calibration curve)
Linearity was demonstrated with six different concentration levels 
for both FFD and FP, which were found to be linear in the range of 
1–3.5 μg/spot for FFD and 10–60 μg/spot for FP. The values are given 
in Table 1. Regression coefficient and concentration of the drugs 
correlated well. The calibration curves are shown in Figs. 4 and 5. The 
residual plots are shown in Figs. 6 and 7.
Precision
The values of intraday and interday precision are given against sample 
application and scanning of peak area and results are expressed in terms 
of percentage relative standard deviation (RSD). The measurement of 
peak areas at three different concentration levels showed a low value of 
percentage RSD (<2) for intra- and inter-day variation, which suggested 
that the method was precise (Table 2).
Repeatability
The percentage RSD for repeatability of the drugs was found to be <2 
(i.e., 1.05 for FFD and 1.17 for FP). Hence, it was concluded that the 
proposed method for estimation of FFD and FP was repeatable in 
nature; the data for the same are shown in Table 3.
Table 3: Repeatability study for FFD and FP (n=6)
Drug Concentration 
(µg/spot)


















FFD: Formoterol fumarate dihydrate, FP: Fluticasone propionate,  
RSD: Relative standard deviation
Table 4: Recovery studies for FFD and FP by HPTLC method (n=3)
Label claim 
(µg/capsule)
% Level of spiked 
standard drug




% Recovery Mean (%) 
recoveryFormulation Pure drug Total amount (μg)
FFD 6 µg 80 0.6 0.5 1.1 1212 1.09 99.09 99.13
100 0.6 0.6 1.2 1279 1.189 99.08
120 0.6 0.7 1.3 1348 1.29 99.23
FP 100 µg 80 10 8 18 28136 17.83 99.05 99.22
100 10 10 20 30195 19.87 99.35
120 10 12 22 32196 21.84 99.27
FFD: Formoterol fumarate dihydrate, FP: Fluticasone propionate, RSD: Relative standard deviation, HPTLC: High-performance thin-layer chromatography
Table 5: Results of robustness evaluation of FFD and FP (n=3)
Condition FFD FP
Average area % RSD Average area % RSD
A: Change in amount of toluene in mobile phase composition
Toluene: ethyl acetate: formic acid(5.9:4:0.1% v/v/v) 1413 1.13 57047 1.14
Toluene: ethyl acetate: formic acid (6.1:4:0.1% v/v/v) 1471 1.12 57006 1.12
B: Change in saturation time (min)
15 min 1433 1.10 56953 1.13
25 min 1464 1.14 57118 1.07
C: Time from spotting to chromatography (+10 min) 1433 1.10 56833 1.10
D: Time from chromatography to scanning (+10 min) 1407 1.13 57426 1.11
FFD: Formoterol fumarate dihydrate, FP: Fluticasone propionate, RSD: Relative standard deviation
Fig. 12: Densitogram of degradation products of formoterol 
fumarate dihydrate (FFD) and fluticasone propionate (FP) after 
exposure of solid drugs direct to sunlight during daytime for 2 
days at Rf value 0.48 (peak 2; FFD 4) and 0.85 (peak 4; FP 4)
Fig. 11: Densitogram of degradation products of formoterol 
fumarate dihydrate (FFD) and fluticasone propionate (FP) in 3% 
H2O2 at 50°C after 1 h at Rf value 0.50 (peak 2; FFD 4) for FFD and 
0.72 (peak 4; FP 1), 0.84 (peak 5; FP 3) for FP
Accuracy
To check the accuracy of the method, recovery studies were carried out 
by standard addition of drug solution to pre-analyzed sample solution at 
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three different levels 80, 100, and 120%. The percent mean recoveries 
were found to be 99.13% for FFD and 99.22% for FP (Table 4).
Specificity
The peak purity of FFD and FP was assessed by comparing their 
respective densitograms at peak start, peak apex, and peak end positions 
of the spot, i.e., r (start, middle) = (0.25–0.27) and r (middle, end) = 
(0.27–0.29) for FFD and r (start, middle) = (0.57–0.65) and r (middle, 
end) = (0.65–0.68) for FP. The chromatogram of capsule sample showed 
peaks at Rf values of 0.27 and 0.64 for FFD and FP, respectively (Fig. 8), 
indicating that there is no interference of the excipients present in the 
capsule formulation indicating the specificity of the method.
Robustness
The percentage RSD of the peak areas was calculated for change in 
the amount of toluene in mobile phase composition, change in time 
from spotting to chromatography and time from chromatography to 
scanning, change in saturation time and change in solvent run distance 
(Table 5).
Limits of detection and quantitation
The LOD is the smallest concentration of the analyte that gives a 
measurable response (signal to noise ratio of 3:1). The LOD was found 
to be 0.3 µg/spot for FFD and 0.2 µg/spot for FP. LOQ is the smallest 
concentration of the analyte, which gives the response that can be 
accurately quantified (signal to noise ratio of 10:1). The LOQ was 
1 µg/spot for FFD and 0.6 µg/spot for FP, which indicates that the 
proposed method was sensitive enough to detect the drugs at very low 
concentration level (Table 6).
Forced degradation studies
Selectivity of the method was demonstrated by enhancing degradation 
of FFD and FP under various stressed conditions (acid, base hydrolysis, 
oxidation, neutral, and photochemical), to show that FFD and FP were 
separated from their possible degradation products. The number of 
degradation products with their Rf was calculated and listed in Table 7.
Acid-induced degradation
The densitograms for acid degraded FFD and FP showed additional 
peaks at Rf 0.15, 0.47 and 0.72, respectively. The rate of degradation for 
FFD (18.00%) was more as compared to FP (13.22%) in acid-induced 
degradation (Fig. 9).
Base-induced degradation
The degradation in 10 ml of 0.1 N NaOH at 50°C was so fast that around 
18.12% of FP was degraded in 15 min, forming one degradation product 
at Rf 0.78 and 9.11% of FFD was degraded with one degradation product 
at Rf value 0.42 (Fig. 10).
Oxidative degradation
The drugs were found to be susceptible to oxidative degradation. The 
densitogram of hydrogen peroxide-induced degradation showed the 
additional peaks at Rf value 0.50 for FFD and 0.72 and 0.84 for FP, 
respectively. The percent of degradation was found to be 13.06% for 
FFD and 11.29% for FP (Fig. 11).
Photolytic degradation
FP and FFD were found to undergo photolytic degradation after 
exposure of solid drugs direct to sunlight during the daytime for 2 days. 
Degradation of FFD was observed (5.74%) with degradation product 
at Rf value 0.48 and 18.37% degradation was observed for FP with an 
additional peak at Rf value 0.85 (Fig. 12).
Neutral degradation
The FFD and FP showed two additional peaks when treated in water at 
50°C for 30 min. Peaks of degraded products were found at Rf value 0.47 
for FFD and 0.74 for FP (Fig. 13).
DISCUSSION
The proposed stability indicating HPTLC method provides precise, 
accurate, and reproducible quantitative analysis for simultaneous 
estimation of FFD and FP in bulk drug and pharmaceutical dosage form. 
The method was validated as per the ICH guidelines. The linearity was 
found to be in the range of 1–3.5 μg/spot and 10–60 μg/spot for FFD 
and FP, respectively. Percentage RSD of intraday and interday precision 
was found to be <2% making the method more precise. Degradation 
study revealed that FFD was most prone to degradation under acid 
(18%, 30 min) stress followed by the stress conditions such as neutral 
Fig. 13: Densitogram of degradation products of formoterol 
fumarate dihydrate (FFD) and fluticasone propionate (FP) in 
neutral hydrolysis after 30 min at Rf value 0.47 (peak 2; FFD 2) 
and 0.74 (peak 4; FP 5)
Table 6: Results of LOD and LOQ
Drug LOD (µg/spot) LOQ (µg/spot)
FFD 0.3 1
FP 0.2 0.6
FFD: Formoterol fumarate dihydrate, FP: Fluticasone propionate, LOD: Limit of 
detection, LOQ: Limit of quantification
Table 7: Summary of degradation studies for FFD and FP
Stressed condition FFD FP
Rf (FFD) % Degradation DP of FFD at Rf Rf (FP) % Degradation DP of FP at Rf
Acid, 0.1 N HCl at 50°C after 30 min 0.26 18.00 FFD 1–0.15,
FFD 2–0.47
0.64 13.22 FP 1–0.72
Base, 0.1 N NaOH at 50°C after 15 min 0.26 9.11 FFD 3–0.42 0.63 18.12 FP 2–0.78
Oxidative, 3% H2O2 at 50°C after 1 h 0.27 13.06 FFD 4–0.50 0.63 11.29 FP 1–0.72,
FP 3–0.81
Photolytic, exposure of solid drugs to 
sunlight during the daytime for 2 days
0.27 5.74 FFD 4–0.48 0.64 18.37 FP 4–0.85
Neutral, distilled water at 50°C after 30 min 0.27 14.34 FFD 2–0.47 0.64 13.22 FP 5–0.74
FFD: Formoterol fumarate dihydrate, FP: Fluticasone propionate, DP: Degradation product
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(14.3%, 30 min), base (9.11%, 15 min), oxidative (13.06%, 1 h), and 
photolytic (5.74%, 2 days). FP showed more degradation in basic 
(18.12, 15 min) and photolytic (18.3%, 24 h) conditions.
CONCLUSION
The developed method was able to separate the drugs from its 
degradants and impurities. It can be successfully applied as stability 
indicating method for combination of FFD and FP. Thus, the reported 
method is of considerable importance and has sound industrial 
applicability for quality control and stability analysis of FFD and FP 
from bulk drug and pharmaceutical dosage form.
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